Citizens JMP raised the firm’s price target on Nuvation Bio (NUVB) to $8 from $6 and keeps an Outperform rating on the shares. Nuvation Bio reported Q4 financial results and highlighted 204 new Ibtrozi starts in Q3, the analyst tells investors in a research note. The launch trajectory is exceeding expectations and is already outpacing ROS1 launches in recent memory, Citizens says.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVB: